What's New in the Treatment of Migraine?
- 1 September 2019
- journal article
- research article
- Published by Wolters Kluwer Health in Journal of Neuro-Ophthalmology
- Vol. 39 (3) , 352-359
Abstract
Background: Migraine is very common. In addition to affecting visual quality of life, migraine can be seen in the neuro-ophthalmology office with regularity. Treatment is critical to assist in the reduction of disability and symptoms. Knowing the evidence-based new treatments is important for every neuro-ophthalmologist. Methods: Using PubMed, and using the term migraine as it related to the terms treatment, evidence-based, calcitonin gene-related peptide (CGRP) inhibitor or antibody, electrical stimulation, vagal nerve stimulation, a literature review was performed. Results: Aside from standard well-described and evidence-based therapies for the acute treatment and prevention of migraine, many new therapies have received FDA approval. In this review, we summarize the contribution of new classes of migraine-specific therapies: CGRP antibodies (erenumab, fremanezumab, galcanezumab, and eptinezumab) for prevention and inhibitors referred to as gepants (ubrogepant and rimegepant) for acute treatment. We also cover newer medications about to be approved, such as lasmitiditan. Devices, including the hand-held vagal nerve stimulator, supraorbital stimulation, transmagnetic stimulation, and remote electrical stimulation, are now approved by the FDA for treatment of migraine. Conclusion: Many new and exciting therapies exist for the treatment of migraine. Keeping up with this rapidly evolving field is important in reducing disability from the common disease of migraine.Keywords
This publication has 57 references indexed in Scilit:
- OnabotulinumtoxinA for chronic migraine: efficacy, safety, and tolerability in patients who received all five treatment cycles in the PREEMPT clinical programActa Neurologica Scandinavica, 2013
- Migraine prevention with a supraorbital transcutaneous stimulatorNeurology, 2013
- The 2012 AHS/AAN Guidelines for Prevention of Episodic Migraine: A Summary and Comparison With Other Recent Clinical Practice GuidelinesHeadache: The Journal of Head and Face Pain, 2012
- OnabotulinumtoxinA for Treatment of Chronic Migraine: Pooled Results From the Double‐Blind, Randomized, Placebo‐Controlled Phases of the PREEMPT Clinical ProgramHeadache: The Journal of Head and Face Pain, 2010
- The Epidemiology of Primary Headache DisordersSeminars in Neurology, 2010
- OnabotulinumtoxinA for treatment of chronic migraine: Results from the double-blind, randomized, placebo-controlled phase of the PREEMPT 1 trialCephalalgia, 2010
- OnabotulinumtoxinA for treatment of chronic migraine: Results from the double-blind, randomized, placebo-controlled phase of the PREEMPT 2 trialCephalalgia, 2010
- Acute Treatment of Intractable Migraine With Sphenopalatine Ganglion Electrical StimulationHeadache: The Journal of Head and Face Pain, 2009
- High-Frequency Transcranial Magnetic Stimulation on Motor Cortex of Patients Affected by Migraine With Aura: A Way to Restore Normal Cortical Excitability?Cephalalgia, 2009
- The trigeminovascular system and migraine: Studies characterizing cerebrovascular and neuropeptide changes seen in humans and catsAnnals of Neurology, 1993